Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Periodontitis Patients

NCT07827391 | Active Not Recruiting

• 1 other identifier: 2026-SAEK-0562
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This retrospective comparative study aims to evaluate the effects of resveratrol and omega-3 supplementation as adjuncts to non-surgical periodontal treatment on clinical periodontal parameters in patients with periodontitis. A total of 60 systemically healthy, non-smoking patients will be evaluated and categorized into three groups according to their recorded supplementation status: a resveratrol group receiving non-surgical periodontal treatment plus resveratrol supplementation (n=20), an omega-3 group receiving non-surgical periodontal treatment plus omega-3 supplementation (n=20), and a non-supplemented control group receiving non-surgical periodontal treatment alone (n=20). Periodontal outcomes will be assessed at baseline and at 1 and 3 months after non-surgical periodontal treatment using probing pocket depth, clinical attachment level, plaque index, gingival index, and bleeding on probing. The study aims to compare the clinical periodontal outcomes of the three groups and determine whether adjunctive resveratrol or omega-3 supplementation is associated with additional clinical benefits beyond non-surgical periodontal treatment alone.

Conditions

Periodontitis

Keywords

Resveratrol; Omega-3 fatty acid; Periodontitis; Non-surgical periodontal treatment; Clinical attachment level

Outcome Measures

Primary Outcomes (1)

• Clinical attachment level (CAL)

  Clinical attachment level (CAL) was measured in millimeters using a Williams periodontal probe as the distance between the cementoenamel junction (CEJ) and the base of the periodontal pocket. In sites with gingival recession, the distance from the CEJ to the gingival margin was incorporated into the CAL measurement. Measurements were recorded at six sites per tooth: mesiobuccal/mesiolabial, mid-buccal/midlabial, distobuccal/distolabial, mesiolingual/mesiopalatal, mid-lingual/mid-palatal, and distolingual/distopalatal sites.

  Baseline, 1 month, and 3 months

Secondary Outcomes (4)

• Probing Pocket Depth (PPD)

  Baseline, 1 month, and 3 months

• Plaque Index (PI)

  Baseline, 1 month, and 3 months

• Gingival Index (GI)

  Baseline, 1 month, and 3 months

• Bleeding on Probing (BOP)

  Baseline, 1 month, and 3 months

Study Arms (3)

Trans-resveratrol

Patients who received trans-resveratrol supplementation at a total daily dose of 250 mg twice daily (500 mg/day total), during non-surgical periodontal treatment.

Dietary Supplement: trans-resveratrol

Omega-3 fatty acids

Patients who received omega-3 fatty acid supplementation at a total dose of 1320 mg, including 640 mg EPA and 480 mg DHA, during non-surgical periodontal treatment.

Dietary Supplement: Omega-3 (EPA+DHA)

No supplementation

Patients who underwent non-surgical periodontal treatment without receiving resveratrol or omega-3 supplementation

Dietary Supplement: No supplementation

Interventions

trans-resveratrol DIETARY_SUPPLEMENT

Trans-resveratrol supplementation at a dose of 250 mg twice daily (500 mg/day total) during non-surgical periodontal treatment.

Trans-resveratrol

Omega-3 (EPA+DHA) DIETARY_SUPPLEMENT

Omega-3 fatty acid supplementation at a total daily dose of 1320 mg, including 640 mg EPA and 480 mg DHA, during non-surgical periodontal treatment.

Omega-3 fatty acids

No supplementation DIETARY_SUPPLEMENT

Patients who underwent non-surgical periodontal treatment without receiving resveratrol or omega-3 fatty acid supplementation during the treatment period

No supplementation

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of patients aged 18-65 years who were diagnosed with periodontitis and met the predefined eligibility criteria. A total of 60 patients were included in the study and categorized into three groups according to their recorded supplementation status: a trans-resveratrol supplementation group, an omega-3 supplementation group, and a non-supplemented control group receiving non-surgical periodontal treatment without resveratrol or omega-3 supplementation. All patients received non-surgical periodontal treatment.

You may qualify if:

• Presence of at least 20 natural permanent teeth,
• Age between 18 and 65 years,
• Non-smoker status,
• No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the previous 6 months,
• No known history of hypersensitivity or allergic reactions to resveratrol, omega-3 fatty acids, or dietary supplements containing these components,
• No periodontal treatment within the previous 6 months,
• Absence of any oral or other systemic disease,
• Not being pregnant or lactating.

You may not qualify if:

• Presence of fewer than 20 natural permanent teeth,
• Age younger than 18 years or older than 65 years,
• Current smoking,
• Use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the previous 6 months,
• Known hypersensitivity or allergic reactions to resveratrol, omega-3 fatty acids, or dietary supplements containing these components,
• Periodontal treatment within the previous 6 months,
• Presence of any oral or systemic disease,
• Pregnancy or lactation.

Sponsors & Collaborators

• Izmir Katip Celebi University: lead

Study Sites (1)

İzmir Katip Çelebi University, Faculty of Dentistry

Izmir, İzmir, 35640, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Periodontitis

Interventions

Resveratrol; Docosahexaenoic Acids

Condition Hierarchy (Ancestors)

Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Stilbestrols; Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polyphenols; Phenols; Fatty Acids, Omega-3; Dietary Fats, Unsaturated; Dietary Fats; Fats; Lipids; Fatty Acids, Unsaturated; Fatty Acids; Fish Oils; Oils

Study Officials

• MEHMET SAĞLAM, Professor

  Izmir Katip Celebi University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Assistant

Study Record Dates

• First Submitted: September 14, 2026
• First Posted: September 18, 2026
• Study Start: January 1, 2025
• Primary Completion (Estimated): March 15, 2027
• Study Completion (Estimated): March 15, 2028
• Last Updated: September 18, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)